Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Biotechnology

Healthcare
$6.30 -4.15%

-$0.41 today

Market cap
$192.17M
Beta
0.78
P/E (TTM)
-1.7
EPS (TTM)
-$5.65
52W Low $5.60High $15.57

Volume 0.17M

Average 0.26M

RNAC Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Cartesian Therapeutics, Inc.NASDAQ: RNAC

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $19.46M rose 32.6% year over year, ahead of the +25.5% change in trailing-twelve-month research & development. Sequentially, it rose 32.5% from the prior quarter. Over 3 fiscal years it compounded at -7.1% a year.

Context

  • Research & development amounted to 2074.9% of revenue in FY2025, up 1959.0 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +32.6% holds above the trailing-twelve-month pace of +25.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$19.46M+32.5% QoQ
Last fiscal yearDec 2025
$58.03M+28.7% YoY
LTMMar 2026
$62.82M+25.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.6%——
1 year+28.7%——
3-year CAGR-7.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
58.03M USD
Year-over-year change
+28.7%
4-year CAGR
-4.1%

Research & Development vs competitors

How RNAC compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +25.5% is the 6th highest of 9, against a peer median of +44.8%.
  • Research & development amounts to 3539.3% of revenue for RNAC, versus a peer median of 184.8%.
RNAC Competitors
Research & Development for RNAC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€83.61M EUR-8.0%+11.4%1865.0%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$62.82M USD+25.5%-7.1%3539.3%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$60.48M USD+28.2%+38.4%184.8%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$57.75M USD+141.5%+89.7%—
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$55.01M USD+74.4%+17.0%93235.6%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$40.3M USD-12.6%+4.1%—
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$27.18M USD+72.6%+29.4%—
MDWDMediWound Ltd.LTM Mar 2026$16.62M USD+61.4%+12.0%114.8%
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$3.93M USD———
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$205K USD-48.5%-58.6%0.4%
Peer median (excluding RNAC) —+44.8%+14.5%184.8%

Competitors are the stored peer set for RNAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue85.08M110.78M26M38.91M2.8M
Cost of Revenue02.04M000
Gross Profit85.08M108.74M26M38.91M2.8M
Gross Margin100.0%98.2%100.0%100.0%100.0%
Research & Development68.74M72.38M71.26M45.11M58.03M
Selling, General & Admin20.94M23.86M40.45M30.13M31.47M
Operating Expenses89.67M94.2M112.42M82.81M89.5M
Depreciation & Amortization1.72M2.04M843K1.15M2.96M
EBITDA(5.16M)39.84M(235.03M)(75.99M)(136.54M)
EBITDA Margin-6.1%36.0%-903.8%-195.3%-4881.5%
Operating Income(4.6M)14.54M(86.42M)(43.9M)(86.71M)
Operating Margin-5.4%13.1%-332.3%-112.8%-3099.9%
Interest Income004.96M7.39M6.58M
Interest Expense2.84M3.03M2.83M00
Other Income / Expenses(5.12M)20.23M(152.29M)(33.24M)(52.79M)
Income Before Tax(9.72M)34.77M(238.71M)(77.14M)(139.5M)
Pre-Tax Margin-11.4%31.4%-918.0%-198.2%-4987.3%
Income Tax Expense15.97M(609K)(19M)287K(9.19M)
Net Income(25.69M)35.38M(219.71M)(77.42M)(130.3M)
Net Margin-30.2%31.9%-844.9%-199.0%-4658.6%
EPS (Basic)(6.74)7.33(49.76)(2.99)(5.02)
EPS (Diluted)(6.60)3.00(49.76)(3.29)(5.02)
Weighted Avg Shares3.18M4.02M5.17M25.91M25.97M
Weighted Avg Shares (Diluted)3.18M4.05M5.17M23.69M25.97M

Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Intrinsic Alpha fair value

Locked

Current Price

$6.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.